Foundation Medicine Inc (FMI) : Murphy Michael R scooped up 132,029 additional shares in Foundation Medicine Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 1,558,392 shares of Foundation Medicine Inc which is valued at $26.9 Million.Foundation Medicine Inc makes up approximately 9.19% of Murphy Michael R’s portfolio.
Other Hedge Funds, Including , Dekabank Deutsche Girozentrale reduced its stake in FMI by selling 2,700 shares or 15.43% in the most recent quarter. The Hedge Fund company now holds 14,800 shares of FMI which is valued at $255,596.Ipswich Investment Management boosted its stake in FMI in the latest quarter, The investment management firm added 9,400 additional shares and now holds a total of 21,800 shares of Foundation Medicine Inc which is valued at $376,486. Foundation Medicine Inc makes up approx 0.18% of Ipswich Investment Management’s portfolio.Teacher Retirement System Of Texas boosted its stake in FMI in the latest quarter, The investment management firm added 298 additional shares and now holds a total of 1,260 shares of Foundation Medicine Inc which is valued at $21,760.Proshare Advisors reduced its stake in FMI by selling 2,488 shares or 8.45% in the most recent quarter. The Hedge Fund company now holds 26,953 shares of FMI which is valued at $457,392. Foundation Medicine Inc makes up approx 0.01% of Proshare Advisors’s portfolio.Schwab Charles Investment Management Inc boosted its stake in FMI in the latest quarter, The investment management firm added 816 additional shares and now holds a total of 46,775 shares of Foundation Medicine Inc which is valued at $793,772.
Foundation Medicine Inc closed down -0.01 points or -0.05% at $18.66 with 1,56,198 shares getting traded on Wednesday. Post opening the session at $18.8, the shares hit an intraday low of $18.29 and an intraday high of $18.98 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Foundation Medicine Inc reported $-0.50 EPS for the quarter, beating the analyst consensus estimate by $ 0.22 according to the earnings call on May 3, 2016. Analyst had a consensus of $-0.72. The company had revenue of $30.40 million for the quarter, compared to analysts expectations of $26.04 million. The company’s revenue was up 57.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.59 EPS.
Foundation Medicine Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies including leukemia lymphoma myeloma and various sarcomas and pediatric cancers are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.